Google+ Followers [Join for FREE]

Tuesday, December 23, 2014

Hefty Price Tag on Viral Hep C "Cure".... do you have $85K?

FDA approves new hepatitis C combination treatment.

The Wall Street Journal (12/19, Loftus, Subscription Publication) reported that the FDA approved AbbVie Inc.’s new treatment for hepatitis C, called Viekira Pak, after clinical trials showed that more than 90% of people with the most common subtype of hepatitis C in the US, Genotype 1, were cured. Viekira Pak consists of three new medicines, paritaprevir, ombitasvir and dasabuvir, in addition to one older drug, ritonavir. The treatment regimen will reportedly cost $83,319 per patient for the standard 12-week treatment, which is below the price tags on either of Gilead Science Inc.’s hepatitis C treatments: Sovaldi (sofosbuvir) or Harvoni (ledipasvir and sofosbuvir), costing $84,000 and $94,500, respectively.


Hi-Dose Vitamin C IV infusions at about $100/infusion which has fewer side effects and likely better efficacy is a bargain price.  Twice weekly IV VIt C infusions for a few months w/ Liposomal on days not infused....  Human clinical case reports show cure (Dr. T. Levy reports in his book "Primal Panacea")... for more visit 

Source:  From AMA Morning Rounds...

Friday, December 19, 2014

Plaques Tangles Amyloid Inflammation Biomarkers Dementia Alzheimers

Proven ways to detect and assess your risk for cognitive decline, dementia and Alzheimer's Disease.

Proven ways to treat to prevent PRIOR to developing amyloid plaques and tangles.  A drug free approach with proven human published studies.
1.  Get yourself tested
           - ApoE 4-allele assessment
           - Methylation Pathway (MTHFR phenotype 
                + Methylation Pathway assessment

2.  Inflammatory Marker assessment (at least 5)

3.  Tx with customized Free-Radical Scavengers
           - Antioxidants
           - Research Proven Agents (those with greatest bio-availability)

4.  Get started early, by the time you are forgetting about this article it is too late.  AD can be prevented, but cannot be reversed.

We come to YOU!

Sunday, November 9, 2014

Dr. Saleeby's MUST READ LIST...

Click on this Link to take you to and you can order and have shipped the following:

Dr. Saleeby's  "Wonder Herbs: A guide to three adaptogens."  (2016).

"Stop the Thyroid Madness, II"  where Dr. Saleeby authored Chapter 3 on NDT  (2014).

Dr. Barry Sear's "A week in the Zone"... helpful anti-inflammatory dietary recommendations, eliminate diabetes, reduce weight, live healthy.

Dr. Michael Ozner's book:  "Heart Attack Proof".

Pam McDonald's book on Apo E.

Dr. Horowitz's book on Chronic Illness and Lyme Dz. (2013)

Dr. Thomas Levy's "Primal Panacea" (2012)

and others.....


Saturday, November 1, 2014

Priority Health + HealthWave = GREAT Patient Care.

Priority Health now on board with HealthWave, to help patients with ease of checkout and order the very best supplements/products that Dr. Saleeby and Richardson prescribe.

 Link to HealthWave

Friday, October 31, 2014

House Calls available in parts of SC and NC... Chronic Disease Patients do not have to suffer.

Innovative Medicine: A Patient's Journey with Lyme Disease from Innovative Medicine on Vimeo.

Do you have Chronic Illness that seems to evade routine traditional healthcare paradigms?  Have you been to multiple specialists without definitive answers and placed on one drug after another that seems to just mask your symptoms?  

Maybe it is time to jump ship and turn towards another "way" or "model" that utilizes better diagnostics and therapies.  This video demonstrates one case, a man suffering from Lyme disease, and the therapy that changed the life of one person tremendously.  For more info on our practice visit:  We can even come to you in SC and NC.

Thursday, October 30, 2014

ThumbTack... web presence.

Saturday, October 18, 2014

Lyme Disease, co-infections such as babesia, ehrlichia and bartonella should not be ignored.

Recently attended the 2014 ILADS Lyme Conference in Washington DC in October.

Armed with new knowledge and training in the Dx and Tx of Lyme and associated co-infections with additional training to come via ILADS programs, I will be evaluating folks for Borellia infections (Bb) and co-infections like  BABESIA · EHRLICHIA · BARTONELLA.

For more info call 800.965.8482
member of ILADS

Wednesday, September 3, 2014

Free Health and Wellness Webinar

 Register today for this Free Webinar

A FREE Evolution of Medicine ONLINE summit. This may be of interest to many of my patients. Use the link below to register:

Monday, September 1, 2014

NC Medical Board watches out for its people...

“For the benefit and protection of the people of North Carolina…”

Newsletter: Forum, No. 3 2014
Categories: President's Message,

Image for “For the benefit and protection of the people of North Carolina…”As you know, the Medical Board’s mission is to protect the public. One of the most important ways it does this is by intervening to protect unsuspecting patients from treatments that are outside accepted standards of care and, at times, risky.

This may not sound controversial, but it can quickly become so when we delve into specifics. In this article, I will give you my personal take on how the Board attempts to balance challenging and sometimes competing interests when considering cases that involve nonstandard treatments.

Medicine by its nature is constantly evolving and new treatments and modalities are developed on an almost daily basis. The best of these are hailed as innovations that extend and improve life – and some even live up to their promise. The worst are eventually denounced as snake oil that, at best, empty patients’ pockets while filling them with false hopes and, at worst, harm or kill them.

Often, though, things are not so black and white. Some cases the Board reviews involve treatments that are apparently without scientific basis, yet relatively benign and, at times, anecdotally effective. When reviewing these situations, Board Members must ask this important and difficult question: When should the Board interfere with a patient’s freedom to choose in order to protect them from financial exploitation or false hope when the potential for harm is low?

The HCG example
In 2013, the Policy Committee of the Board amended its position statement entitled, “The treatment of obesity,” to indicate that the Board does not consider human chorionic gonadotropin (HCG) to be an appropriate treatment for obesity. The decision, which the full Board approved, was based on two main factors: 1. The Board’s belief that there is no proven scientific basis for the treatment of obesity with HCG and 2. Some evidence of risks associated with the therapy.

Months after the amended position statement was approved, the Board reviewed a complaint regarding a licensee who prescribed HCG for weight loss. This prompted a reexamination of information about the treatment. And while nothing changed the Board’s view of the efficacy of this treatment, upon further review of the risks, the Board concluded that the potential for patient harm is not as significant as initially perceived. The Board voted to strike the language referring to using HCG for weight loss as inappropriate from the Board position statement.

It’s somewhat unusual for the Board to reverse course on an issue in such a relatively short period of time. But the case of HCG is an excellent example of the type of issue the Board is required to make decisions about on a regular basis.

Should patients be free to consent to treatments that we, as trained medical professionals, find to be entirely without scientific basis? Should patients and their medical providers have total freedom to decide what treatments are used? Or are some controls acceptable? For example, should the Board give its blessing for providers to give patients their treatments of choice as long as they are adequately informed that the care falls outside of accepted standards? How does risk factor into the Board’s obligation to protect? How much risk is acceptable for the patient to assume?

Treatment cost is yet another consideration. Current law gives the Board the authority to protect patients from financial exploitation by licensees. A review of cases over the years provides numerous examples of situations where the Board has stopped licensees from benefiting from the aggressive marketing of costly therapies of unproven clinical value. Should the Board always step in to protect patients’ pocketbooks? Only when large sums of money change hands? Only when there is no informed consent or there is a vulnerable patient?

The issues the Board considers go well beyond whether a particular weight loss treatment safely melts pounds. The Board has made difficult decisions in cases involving nonstandard treatments in the fields of oncology, infectious disease and mental health, just to name a few.

These decisions are never made lightly or easily. And, the Board is rarely of one mind at the outset of these discussions. At times, some Board members are strongly motivated to act to protect patients not only from physical harm or financial exploitation but also from the false hopes promised by a treatment in which the Board has no confidence. Others on the Board are inclined to stay out of such situations, provided the threat of patient harm is minimal. Regardless of Board members’ individual views, the NCMB employs the same objective framework when evaluating these difficult cases. At minimum, the Board weighs the following factors:

1. Does it work? In evaluating any case that involves clinical medicine, the Board considers accepted and prevailing standards of care and, in the specific instance of care that is experimental or otherwise unestablished, available evidence that demonstrates the treatment’s safety and efficacy. The Board acknowledges that many, many treatments and modalities are used successfully and on a routine basis without the benefit of placebo controlled double blind clinical trials. That said, we look to published research and authoritative consensus statements when considering any therapy.

2. What are the risks? All medical care, at the end of the day, is a balance between the potential benefits and the recognized risks. When considering the appropriateness of any treatment under review, the Board always considers known risks to the patient as well as information regarding potential benefits and clinical efficacy.

3. Is the cost exploitive? The cost of treatments under review is often an important consideration, particularly in situations where care may be outside accepted standards and/or those where care is not covered by medical insurance. In the past, the Board has taken action to intervene when it determines that licensees have exploited patients financially by recommending costly treatments that either don’t conform to the standard of care or have been used in an overaggressive manner.

4. Is the patient informed? As part of its review of any case involving experimental or nonstandard treatments, the Board carefully examines the licensee’s process for obtaining informed consent from patients. It is the Board’s position that any patient who is considering a nonstandard treatment should be clearly and thoroughly informed that the treatment falls outside of the norm well in advance of making a final decision. The licensee should clearly explain all potential benefits and all recognized risks of treatment. In numerous cases the Board has reviewed, the Board has permitted licensees to continue offering nonstandard therapies as long as a robust informed consent process is in place – especially when the nonstandard therapy is used in combination with other established treatments.

These factors provide a solid framework for evaluating and making decisions in cases that involve new and nonstandard treatments that come to the Board’s attention. These cases are rarely easy, and I don’t see that changing. Options for complementary and alternative therapies abound and Internet access plus the general tendency and expectation for patients to take greater command of their health keeps patient demand for these treatments soaring. Add to this the economic realities of medicine, which motivate licensees to provide treatments that are in demand and, often, more lucrative than established therapies since they are usually not covered by health insurance. These factors, along with innovation in medicine, will keep the Board busy well into the future.

Now, I’d like to hear what you think. How far does the Board’s obligation to protect the public from nonstandard treatments and modalities extend?

comment:  Very nice article.  The board needs to remain both an advocate for NC patients AND physicians.  Often times non-EBM treatments are prescribed and non-FDA approved drugs used to treat patients as part of Standard Practice Guidelines.  The influences of some BigPharma, Governmental and Insurance Industry pressures make delivery of affordable and good healthcare difficult.  While I understand the boards mandate to protect the citizens, I feel very strongly it should also protect the physician's delivering needed healthcare services to those citizens.  Respectfully,   JP Saleeby, MD

Saturday, August 16, 2014

Tumeric to your health!


by Yusuf M. Saleeby, MD
(to be published in upcoming American Fitness magazine)

Turmeric is a rather popular herbal these days for its touted reputation at knocking down inflammation.  We know that inflammation is a major player in everything from heart disease to stroke to cancer.  Controlling inflammation for those with high levels, will yield improvements in their quality of life.  When we think inflammation we often think of painful joints, but inflammation goes way beyond these observable and overt symptoms.  Inflammation (the silent type) has been implicated in heart disease, cancer, dementia (Alzheimer’s disease), diabetes and many other disorders.  Treating inflammation naturally with turmeric makes a lot of sense.  There is evidence abound that this natural and relatively safe therapy works.

Turmeric is produced from the rhizamatous herbal Curcuma longa.  This plant belongs to the ginger family of plants called Zingiberaceae.  There are some 124 species of Curcuma, many used medicinally.  Curcuma zedoaria which is the Javanese white turmeric root while having medicinal properties of its own, should not be confused with the C. longa species that we are considering and discussing here.  So pick and choose your turmeric wisely.  Not only the plant, genus and species, but also the processing and preparation to obtain a high quality, bioavailable, final product achieving highest medicinal value must be considered.
In the 13th chapter of the book Herbal Medicine: Biomolecular and Clinical Aspects. 2nd Edition, Sahdeo Prasad and Bharat Aggarwal discuss the history of the medicinal and culinary use of turmeric dating back some 4000-years.  Some three-thousand articles appear in scientific publications over the past 25-years discussing the use of turmeric as a therapeutic in both animal and human studies.  While this short article hits some of the highlights, this book has one of the best and in-depth look at turmeric and curcumin that I have found and is quite heavily referenced for credibility. 1,2,3

In Ayurvedic medicine turmeric is well established for treating a variety of conditions from respiratory to liver disorders, from rheumatism to diabetic wounds.  In traditional Chinese medicine this herbal was used to treat diseases of the gastrointestinal tract. 1,2
 There are studies in the peer-reviewed scientific literature since at least 1985 showing benefit in cancer prevention, as an antioxidant, anti-mutagen, reducer of inflammation, having anti-viral, anti-fungal and anti-microbial properties.  In vivo human trials also conducted in the mid-1980’s until the present showed positive effects of turmeric against cancer, as an anti-cytotoxic agent, and an agent that protects liver cells (hepatocites).  Other studies show its ability to reduce cataracts and showing properties of reduction in serum glucose in diabetics.4,5   Other studies showed neuroprotection, improved healing in wounds and ulcers, as an adjuvant arthritis treatment.  There are even reports of positive effects in atherosclerosis and lipid oxidation reduction.5   A Chinese journal even reports positive effects in respiratory disorders and asthma.6
Turmeric is traditionally prescribed for upset stomach (dyspepsia) at about 500 mg four times daily.  As an anti-inflammatory for osteoarthritis (OA) the dose is usually different.  One study used a specific product called Meriva, ( for a study on arthritis.7 

Those suffering from rheumatoid arthritis (RA) have a slightly different maintenance dose.  A published report utilized a specific formulation of the turmeric constituent, curcumin (BCM-95®,  This proprietary preparation of turmeric is apparently seven-times more bioavailable than the usual commercially available turmeric compounds.8   A 2014 article published on the use of turmeric in a head to head study against a traditional NSAID (ibuprophen/ Motrin®) showed equal or even better reductions in pain and inflammation and lower incidents of adverse events with turmeric.9
Not only the dose, but the preparation is often important with regard to disease and severity of symptoms.10

A few precautions should be mentioned with regard to this spice.  When Turmeric is consumed in the lower doses associated with food consumption it is relatively safe.  However, when used medicinally, larger doses are prescribed and needed to achieve a therapeutic effect.  Supplements contain up to 500 mg per tablet or capsule in general and are prescribed to be taken up to four times a day.  That is around 2000 mg as a therapeutic dose.  Doses this high have the ability to lower blood glucose and blood pressure.11,12  So those on diabetic and BP meds must be careful. 
Turmeric also thins the blood and can cause excessive bleeding when paired with other herbals or drugs with similar properties.  Caution should also be taken with certain medications that can alter a person’s liver metabolism.  Co-administration with agents such as aspirin, warfarin (Coumadin®), non-steroidals and anti-platelet drugs should warrant careful observation and monitoring.  Additionally, herbals such as angelica, clove, Danshen, garlic, ginger and Ginkgo biloba, ginseng and willow root can cause bruising and bleeding.  A National Institute of Health web site reports concerns of turmeric use and gallbladder disease.  Gallstones and bile duct obstruction with turmeric use can worsen.13,14   In pregnancy, turmeric can promote uterine bleeding, so it is not advised in the pregnant and nursing mothers.15

Turmeric contains over 100 components after intense phytochemical analysis by researchers, but the main root extracts of interest are the volatile oils containing turmerone and the coloring agents called curcuminoids.  Volatile oils include d-α-phellandrene, d-sabinene, cinol, borneol, zingiberene, and sesquiterpenes.  Curcuminoids consist of demethoxycurcumin, 5’-methoxycurcumin and dihydrocurcumin, all being natural antioxidants and possessing potent pharmacological properties.  Turmeric happens to be a good source of the omega-3 fatty acid and αlpha-linolenic acid, both sharing anti-inflammatory and anti-oxidant properties and useful in maintaining health.  Some components are beneficial at enhancing the immune system, while others essentially kill cancer cells.16,17,18

Before turmeric can be used the rhizomes must be processed.  Whether for medicinal use or as a culinary spice, the hard rhizomes are first boiled or steamed in an alkaline environment.  Traditionally, in India the process involved earthenware filled with water and the rhizomes and covered with leaves and a layer of cow dung.  The ammonia in the cow dung reacts with the turmeric to produce the final product.  For obvious hygienic reasons this method today is discouraged, in place of the manure, sodium bicarbonate is used to achieve about a 0.1% alkaline water solution.  Boiling lasts between 40-minutes to 6 hours depending on the region and method of preparation.  Once in a powder form the coloration remains indefinitely, but the flavor and medicinal potency diminishes with time and sun exposure.1

The beneficial effects of turmeric over a 4000-year history were historically achieved through simple dietary intake with food consumption.  Health benefits were realized even at low doses, over protracted periods of time.  The activities and used in medicine of the golden spice turmeric include antibacterial and antiviral activity, anti-inflammatory, antitumor and antioxidant properties, and for many years in regional traditional medicine it saw heavy use as a digestive system aid.2,3   Turmeric has been shown to exhibit antiseptic properties, cardioprotective, hepatoprotective and nephroprotective effects in contemporary research studies.19  Some believe it to impart radioprotective protections as well.20

In closing, the ubiquitous golden-yellow spice found throughout India in curried dishes has proven itself quite a safe and useful medicinal herbal.  When used correctly in the proper form and dose, it can impart healing properties on a wide range of human disorders.

Yusuf M. Saleeby, MD is an integrative age management physician.  He has authored a book on Adaptogen Herbs and most recently a chapter in a 2014 publication on Hypothyroidism.  He is a regular contributor to American Fitness magazine.  He exhausts gentle integrative treatment modalities before the consideration of pharmaceuticals in his clinical practice.  For more information visit

Turmeric is helpful in:

Ø  Reducing inflammation and pain in arthritis conditions.  A clear winner in a recent clinical trial going up against Motrin®.9

Ø  Reducing pain and inflammation in Rheumatoid Arthritis.21

Ø  Reduces the risk and occurrence of dementia (Alzheimer’s Disease).  New studies demonstrate a very useful therapy in preventing neurodegenerative disease.12,22

Ø  Reducing cataracts in diabetics.23

Ø  Reducing serum glucose levels in those with insulin resistance and diabetes.24

Ø  Reducing blood pressure in those with elevated BP (hypertension).25

Ø  Improvement in erectile function (ED) in men.  More effective and safer than Viagra®.26




1.       Prasad S, Aggarwal BB. Turmeric, the Golden Spice: From Traditional Medicine to Modern Medicine. In: Benzie IFF, Wachtel-Galor S, editors. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd edition. Boca Raton (FL): CRC Press; 2011.

2.       Krishnaswamy K. Traditional Indian spices and their health significance. Asia Pac J Clin Nutr. 2008;17 Suppl 1:265-8.

3.       Pari L, Tewas D, Eckel J. Role of curcumin in health and disease. Arch Physiol Biochem.2008;114(2):127-49.

4.       Miyakoshi M, Yamaguchi Y, Takagaki R. et al. Hepatoprotective effect of sesquiterpenes in turmeric. Biofactors. 2004;21:167–70.

5.       Araújo CC, Leon LL. Biological activities of Curcuma longa L., Mem Inst Oswaldo Cruz. 2001 Jul;96(5):723-8.

6.       Li C, Li L, Luo J, Huang N. [Effect of turmeric volatile oil on the respiratory tract]. Zhongguo Zhong Yao Za Zhi. 1998 Oct;23(10):624-5.

7.   Belcaro G, Cesarone MR, Dugall M, et al. Efficacy and safety of Meriva, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Alt Med Rev, 2010:15:337-4.

8.       Antony B, Merina B, Iyer V S, Judy N, Lennertz K, Joyal S. A pilot cross-over study to evaluate human oral bioavailability of BCM-95® CG (BiocurcumaxTM), a novel bioenhanced preparation of curcumin . Indian J Pharm Sci, 2008;70:445-9.

9.       Kuptniratsaikul V, Dajpratham P, Taechaarpornkul W, Buntragulpoontawee M, Lukkanapichonchut P, Chootip C, Saengsuwan J, Tantayakom K, Laongpech S. Efficacy and safety of Curcuma domestica extracts compared with ibuprofen in patients with knee osteoarthritis: a multicenter study. Clin Interv Aging. 2014 Mar 20;9:451-8.

10.   Jäger R, Lowery RP, Calvanese AV, Joy JM, Purpura M, Wilson JM. Comparative absorption of curcumin formulations. Nutr J., 2014 Jan 24;13:11.

11.   Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes. Diabetes Care. 2012 Nov;35(11):2121-7.

12.   Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res., 2005 Apr;2(2):131-6.

13.   Rasyid A, Rahman AR, Jaalam K, Lelo A. Effect of different curcumin dosages on human gall bladder. Asia Pac J Clin Nutr., 2002;11(4):314-8.

14.   National Institutes of Health MedlinePlus:  Turmeric. (accessed 8/22/2014)

15.   Turmeric. University of Maryland’s Medical Reference Guide. (accessed 8/22/2014)

16.   Ruby A. J, Kuttan G, Babu K. D, Rajasekharan K. N, Kuttan R. Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett., 1995;94:79–83.

17.   Selvam R, Subramanian L, Gayathri R, Angayarkanni N. The anti-oxidant activity of turmeric (Curcuma longa). J Ethnopharmacol., 1995;47:59–67.

18.   Ahmed Hamdi OA, Syed Abdul Rahman SN, Awang K, Abdul Wahab N, Looi CY, Thomas NF, Abd Malek SN. Cytotoxic Constituents from the Rhizomes of Curcuma zedoaria. Scientific World Journal, 2014;2014:321943.

19.   Gilani AH, Shah AJ, Ghayur MN, Majeed K. Pharmacological basis for the use of turmeric in gastrointestinal and respiratory disorders. Life Sci., 2005 May 13;76(26):3089-105.

20.   Araújo MC, Dias FL, Takahashi CS. Potentiation by turmeric and curcumin of gamma-radiation-induced chromosome aberrations in Chinese hamster ovary cells. Teratog Carcinog Mutagen. 1999;19(1):9-18.

21.   Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res., 2012 Nov;26(11):1719-25.

22.   Baum L, Lam CW, Cheung SK, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease (letter). J Clin Psychopharmacol, 2008;28:110-3.

23.   Grama CN, Suryanarayana P, Patil MA, Raghu G, Balakrishna N, Kumar MN, Reddy GB. Efficacy of biodegradable curcumin nanoparticles in delaying cataract in diabetic rat model. PLoS One. 2013 Oct 14;8(10):e78217.

24. Dong-wei Zhang, Min Fu, Si-Hua Gao, and Jun-Li Liu, Curcumin and Diabetes: A Systematic Review, Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 636053.

25.   Khajehdehi P, Zanjaninejad B, Aflaki E, Nazarinia M, Azad F, Malekmakan L, Dehghanzadeh GR. Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study. J Ren Nutr. 2012 Jan;22(1):50-7.

26.   Zaahkouk AM, Abdel Aziz MT, Rezq AM, Atta HM, Fouad HH, Ahmed HH, Sabry D, Yehia MH. Efficacy of a novel water-soluble curcumin derivative versus sildenafil citrate in mediating erectile function. Int J Impot Res. 2014 Aug 7.

Wednesday, August 6, 2014

new book on hypothyroidism features Dr. Saleeby


As the first STTM book is a compilation of patient experiences and wisdom concerning successful thyroid treatment, STTM II brings you the wisdom and intelligence of several well-chosen medical practitioners with a focus on the integrative and functional approach to treating thyroid disease! See below who the authors are (click on each one to see a bio) and below that are the chapters!

Dr. Yusuf (JP) Saleeby, MD

Dr. Yusuf (JP) Saleeby, MD is an integrative medical practitioner who treats hypothyroid patients and those likely overlooked with subclinical hypothyroidism with standard and non-conventional therapies.  He authored a book on specialty medicinal herbs Wonder Herbs: A guide to three adaptogens (2006)…
 Read more about Dr. Yusuf (JP) Saleeby, MD
STTM II takes you deeper into certain subjects. See the chapter titles below.


by David Brownstein, MD


by Janie A. Bowthorpe, M.Ed.


The Integrative and Functional Medicine Approach to Thyroid Diseases
by James Yang, MD, MPH and Andrew Heyman, MD, MHSA


Stress, Adrenals, Your Thyroid and You
by Laura R Stone MD, Andrew Heyman, MD MHSA
and Carla Heiser, MS RD LD


Thyroid Replacement Therapy: Natural Desiccated Thyroid (NDT)
by Yusuf (JP) Saleeby, MD


The Unreliable TSH Lab Test.
by Jeffrey Dach, MD


When Normal Ain’t Normal
by Geoffrey T. Bouc, MD


Nutrition and Hypothyroidism
by William D. Trumbower, MD


Hashimoto’s Autoimmune Thyroid Disease
by Jeffrey Dach, MD


Why Are Doctors Like That?
by Nguyen D. Phan, MD


Gluten Intolerance and Thyroid Disease
by Paula Luber, MD


Thyroid Toxicity
by Philip L. Roberts, MD


Moving Forward with Reverse T3:
the Causes and Health Implications.
by Paige Adams FNP, B-C


Methylation, MTHFR and Thyroid Dysfunction
by Benjamin Lynch, ND

Chapter 13

Hypocortisolism: An Evidence Based Review
by Lena D. Edwards, MD, FAARM, FICT;
Andrew H. Heyman, MD MHSA; Sahar Swidan, PharmD

Dr. Saleeby's Blog Archive

About Me

My photo
Charleston; Myrtle Beach, SC; Raleigh-Durham, NC; Orlando, FL, GA, NC, SC, VA, FL, United States